Stock·NYSE·Healthcare
Bristol-Myers Squibb Company (BMY)
- Market cap
- $125.73B
- P/E
- 13.54
- Dividend yield
- 4.09%
- Street target
- $65.50median of 28 analysts
- 52-week range
- $42.52 $68.64
BMY stock forecast today
Where BMY stands today, and what CleaRank Financial AI makes of it.
BMY at a glance
Bristol-Myers Squibb Company (BMY): Buy, 64/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($59.87 and $63.09).
- Earnings BMY beat estimates in 8 of its last 8 quarters, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $5.0M and made no open-market purchases over the last 18 months.
- Valuation P/E of 13.5 against 31.9 for the Healthcare sector: a discount to peers (-58%).
Figures as of October 27, 2026.
CleaRank Financial AI
CleaRank rates Bristol-Myers Squibb Company (BMY) Buy with a model score of 64/100.
The biggest lift comes from valuation, with the P/E of 13.54 57.5% below the sector median (a discount to peers) and the P/S of 2.55 25.0% below its median. Momentum pulls the most in the other direction, since the MACD line is negative. The trend is mixed, with BMY 2.44% below its 50-day average of $63.09 but 2.81% above its 200-day average of $59.87. The price rose 41.85% over the past year.
Only on CleaRank
Figures we compute ourselves from BMY's own price, earnings and insider-filing history. Tap one to see it in context.
BMY stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $61.55 is 2.4% below the 50-day simple moving average of $63.09.Price above its 200-day average ›
The price is 2.8% above the 200-day simple moving average of $59.87.50-day average above the 200-day ›
The 50-day average ($63.09) is 5.4% above the 200-day average ($59.87), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 73% of its 52-week range, between $42.52 and $68.64.
BMY share price
Pick a period: each tab shows how far BMY has moved over it, to the last close.
Today's trading
Where BMY sits inside today's range and its 52-week range.
BMY fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 13.54 is 57.5% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 2.55 is 24.9% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $9.3B on revenue of $49.2B, a net margin of 18.9%.Beat estimates in most recent reports ›
BMY beat the EPS estimate in 8 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 4.09%, or $2.52 a share a year.
Key statistics
The headline figures for BMY.
As of October 27, 2026, BMY trades at $61.55, with a market value of $125.73B, a P/E ratio of 13.54 and a dividend yield of 4.09%.
What the numbers say
CleaRank Financial AI's reading of BMY's valuation, growth and risks.
On earnings, Bristol-Myers Squibb Company (BMY) is valued at 13.54 times, against a median of 31.9 for Healthcare: a discount to peers, with the P/E 57.5% below that median. BMY trades at 2.55 times its sales, 25.0% below the sector median of 3.4. BMY has a market capitalisation of $125.7B.
With revenue growth of 5.70%, BMY is 2.4 percentage points slower than the sector median of 8.1%. The business converts sales into profit at a net margin of 18.87% and an operating margin of 34.42%. It reports a return on equity of 46.60%, above the sector median of 7.3%. The balance sheet and payout round out the picture, with debt-to-equity of 2.02 and a trailing dividend yield of 4.09% ($2.52 a share a year).
EPS of $2.04 versus the $1.60 analysts expected made the July 30, 2026 report a beat of 27.50%. The market agreed: the stock rose 0.69% the following session.
BMY has a clean record of beating estimates, with 8 beats in 8 reports. Beats have not always lifted the shares, though: the stock fell the next day after 4 of them. Back on the February 5, 2026 report, the stock rose 4.15% after a beat of 5.00%. Looking ahead, analysts expect EPS of $6.57 this fiscal year, a rise of 6.8%, and $6.61 next year, a rise of 0.6%.
BMY's average daily move is 1.99%; measured against the S&P 500, its beta is 0.18. Insiders sold $5.0M over the last 18 months and bought none on the open market, though sales of this kind are often planned in advance and say less than purchases would.
BMY against the Healthcare sector
How BMY compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: BMY trades at a notable discount to sector peers (-58%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 14, 2025, BMY has gained 39.6% against a gain of 39.2% for XLV.
Performance against XLV
BMY and the Healthcare sector fund over the same days.
Revenue and earnings
How much BMY sells, and how much of it becomes profit.
Revenue growth: Revenue fell 0.2% in FY2025 to $48.2B, from $48.3B a year earlier.
Profit margin: The net margin was 14.6% in FY2025, up from -18.5% the year before.
Profitable: BMY earned $7.1B in FY2025.
Earnings reality check
Did BMY beat what analysts expected, and how did the stock react?
Earnings record: BMY beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 4 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 30, 2026after close | $1.60 | $2.04 | +27.50% | +0.69% | -1.09% |
| Apr 30, 2026after close | $1.42 | $1.58 | +11.27% | -3.91% | -7.16% |
| Feb 5, 2026after close | $1.20 | $1.26 | +5.00% | +4.15% | +0.57% |
| Oct 30, 2025after close | $1.52 | $1.63 | +7.24% | +0.99% | +2.21% |
| Jul 31, 2025after close | $1.10 | $1.46 | +32.73% | +2.12% | +4.73% |
| Apr 24, 2025after close | $1.50 | $1.80 | +20.00% | -1.62% | +1.89% |
| Feb 6, 2025after close | $1.47 | $1.67 | +13.61% | -0.99% | -2.53% |
| Oct 31, 2024after close | $1.50 | $1.80 | +20.00% | -2.60% | -1.90% |
As of October 27, 2026, BMY has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 4 of those beats; its latest report, on July 30, 2026, came in 27.50% above the estimate and the stock moved +0.69% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
BMY AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 51.3, in neutral territory.RSI above 50 ›
An RSI of 51.3 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank Financial AI analysis of BMY
The score, the reasoning behind it, and what could move the price next.
BMY shows a mixed trend. The stock is trading at $61.55, which places it 2.44% below its 50-day average of $63.09, yet 2.81% above its 200-day average of $59.87. Near the top of its 52-week range, the price is 10.33% below the high of $68.64 and 44.76% above the low of $42.52.
A recent pullback sits inside a stronger longer record: the price fell 2.08% over the past month, fell 3.22% over the past three months and rose 41.85% over the past year. Volume in the last session ran 32.4% below its average, on a day the price fell 0.10%. The 14-day RSI of 51.3 is in the neutral zone, and the MACD line is negative.
Earnings beat ›
The July 30, 2026 report beat the EPS estimate by 27.50%, and the share price rose 0.69% in the first session after it.
Source: Earnings report, July 30, 2026
Analyst downgrade ›
Leerink Partners downgraded it to Market Perform from Outperform on October 5, 2026.
Source: Analyst action, Leerink Partners, October 5, 2026
Rating reaffirmed ›
Wells Fargo kept its Equal-Weight rating on October 13, 2026.
Source: Analyst action, Wells Fargo, October 13, 2026
- Keep an eye on the two closest levels: the 50-day SMA at $63.09 sits above the price, and the 20-day EMA at $61.00 sits below it.
- A 14-day RSI of 51.3 sits in the neutral zone, while the MACD line is negative. Readings above 70 or below 30 would signal stretched momentum.
- The share price rose 0.69% in the first session after the July 30, 2026 report. BMY has beaten estimates in 8 of the last 8 reports.
The trend is mixed: BMY is above its 200-day average at $59.87 but below its 50-day average at $63.09. A close above the 50-day would turn both signals up, and a close below the 200-day would turn both down. The nearest levels are the 20-day EMA at $61.00 below and the 50-day SMA at $63.09 above.
Technical indicators
Momentum and trend for BMY, from its daily closes.
As of October 27, 2026, with BMY at $61.55, its 14-day RSI is 51.3 (neutral territory), its 50-day simple moving average is $63.09 and its 200-day is $59.87.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What BMY moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, BMY's 1-year correlation of daily returns is +0.15 with S&P 500 (SPY), +0.02 with Nasdaq 100 (QQQ), +0.00 with Bitcoin (BTC) and +0.04 with gold (XAU).
BMY price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
10 of 28 analysts rate it a buy or strong buy, 17 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $65.50 is 6.4% above the price.More buy ratings than three months ago ›
10 of 28 rate it a buy now, against 9 of 28 three months ago.
BMY Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 13, 2026 | Wells Fargo | Maintains | Equal-Weight |
| Oct 8, 2026 | Cantor Fitzgerald | Maintains | Neutral |
| Oct 7, 2026 | Morgan Stanley | Maintains | Underweight |
| Oct 5, 2026 | Leerink Partners | Downgrade | Market Perform |
| Sep 16, 2026 | Piper Sandler | Reiterates | Overweight |
| Sep 10, 2026 | HSBC | Maintains | Hold |
As of October 27, 2026, 28 Wall Street analysts cover BMY: 10 rate it a buy or strong buy, 17 a hold and 1 a sell or strong sell. Their 12-month price targets range from $41.00 to $82.00. The median BMY price target is $65.50, 6.4% above the price of $61.55.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
BMY trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
BMY trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from BMY's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much BMY tends to move, against the market and on its own.
BMY price history and drawdowns
BMY's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.99% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 47.2%, from December 2022 to July 2024; the price is still 9.7% below that peak.Most 1-year holds ended higher ›
62% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $16,860, against $42,015 in the S&P 500 (SPY).
BMY Drawdowns & Recovery
As of October 27, 2026, BMY's worst peak-to-trough fall over the last 10 years with dividends reinvested was -47.2% (December 2022 to July 2024); it is still 9.7% below that peak, and 62% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into BMY in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: BMY trailed the S&P 500 over this period: $16,860 against $42,015.
A $10,000 investment in BMY in October 2016 would be worth about $16,860 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to BMY, and which have not.
Strongest month, February: an average of +4.33%, up in 7 of 10 years.
Weakest month, April: an average of -3.64%, up in 4 of 10 years.
This month, October: has averaged +1.08%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, BMY's strongest calendar month has been February (average +4.33%, up in 7 of 10 years) and its weakest April (average -3.64%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
BMY stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in BMY, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in BMY today could grow to about $11,729 by 2030 in the base case, with a 90th-percentile outcome near $22,293 and a 10th-percentile outcome around $6,171. The simulation models price only; at today's 4.09% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
BMY Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $72.19 for BMY by 2030 in the base case, from $61.55 today (1.2x over 4 years). The 10th-percentile path ends near $37.98. These are outcomes of a Monte Carlo simulation run on BMY's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $46.46 | $64.05 | $88.31 | |
| 2028 | $42.33 | $66.66 | $105 | |
| 2029 | $39.78 | $69.37 | $121 | |
| 2030 | $37.98 | $72.19 | $137 |
Method: a lognormal simulation of BMY's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
BMY insider trading
What the people running the company have bought and sold.
BMY insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought BMY shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 27, 2026, BMY insiders reported 6 open-market sales worth $5.0M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Cari Gallman
General Counsel
|
Grant | 4.6K | - |
| Sep 9, 2026 | Cristian Massacesi
Officer
|
Sell | 6.2K | $403.5K |
| Sep 1, 2026 | Bartie Wendy Short
Officer
|
Option | 1.2K | $82.7K |
| Aug 25, 2026 | Phil M Holzer
Officer
|
Sell | 500 | $33.8K |
| Jul 31, 2026 | Cari Gallman
General Counsel
|
Grant | 1.1K | - |
| Jul 31, 2026 | Cristian Massacesi
Officer
|
Grant | 51.2K | - |
| Jun 15, 2026 | Julia A Haller
Director
|
Option | 20.5K | $1.1M |
| Jun 3, 2026 | Bartie Wendy Short
Officer
|
Grant | 8.0K | - |
| May 1, 2026 | Adam Lenkowsky
Officer
|
Grant | 1.4K | - |
| Apr 1, 2026 | David Vincent Elkins
Chief Financial Officer
|
Sell | 30.0K | $1.9M |
| Apr 1, 2026 | Karin Shanahan
Officer
|
Grant | 3.3K | - |
| Mar 10, 2026 | Christopher S Boerner
Chief Executive Officer
|
Grant | 71.5K | - |
| Mar 10, 2026 | David Vincent Elkins
Chief Financial Officer
|
Grant | 63.0K | - |
| Mar 10, 2026 | Cari Gallman
General Counsel
|
Grant | 7.0K | - |
| Mar 10, 2026 | Lynelle Baumgardner Hoch
Officer
|
Grant | 8.2K | - |
| Mar 10, 2026 | Phil M Holzer
Officer
|
Grant | 6.2K | - |
| Mar 10, 2026 | Adam Lenkowsky
Officer
|
Grant | 24.1K | - |
| Mar 10, 2026 | Gregory Scott Meyers
Chief Technology Officer
|
Grant | 25.9K | - |
| Mar 10, 2026 | Robert M Plenge
Officer
|
Grant | 17.5K | - |
| Mar 10, 2026 | Ahn Amanda Poole
Officer
|
Grant | 6.4K | - |
| Mar 10, 2026 | Karin Shanahan
Officer
|
Grant | 25.5K | - |
| Mar 10, 2026 | Bartie Wendy Short
Officer
|
Grant | 5.9K | - |
| Feb 27, 2026 | Benjamin J Hickey
Officer
|
Grant | 3.3K | - |
| Jan 30, 2026 | Benjamin J Hickey
Officer
|
Grant | 10.1K | - |
| Jan 30, 2026 | Gregory Scott Meyers
Chief Technology Officer
|
Grant | 2.5K | - |
| Oct 31, 2025 | Christopher S Boerner
Chief Executive Officer
|
Grant | 3.0K | - |
| Oct 31, 2025 | Gregory Scott Meyers
Chief Technology Officer
|
Grant | 6.3K | - |
| Oct 31, 2025 | Karin Shanahan
Officer
|
Grant | 6.3K | - |
| Oct 2, 2025 | Cari Gallman
General Counsel
|
Grant | 4.6K | - |
| Sep 2, 2025 | David Vincent Elkins
Chief Financial Officer
|
Sell | 56.0K | $2.7M |
| Aug 29, 2025 | Bartie Wendy Short
Officer
|
Grant | 1.2K | - |
| Aug 1, 2025 | Bartie Wendy Short
Officer
|
Sell | 378 | $16.7K |
| Aug 1, 2025 | Cari Gallman
General Counsel
|
Grant | 1.1K | - |
| Aug 1, 2025 | Bartie Wendy Short
Officer
|
Grant | 738 | - |
| Jun 3, 2025 | Christopher S Boerner
Chief Executive Officer
|
Grant | 62.7K | - |
| Jun 3, 2025 | Bartie Wendy Short
Officer
|
Grant | 8.0K | - |
| May 9, 2025 | Benjamin J Hickey
Officer
|
Sell | 97 | $3.7K |
Source: TwelveData, from SEC Form 4 filings
BMY stock forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.